Profusa ' s embeddable continuous biosensor draws $45M from investors

Profusa, a company that is developing connected tissue-implanted biosensors, has raised just over $45 million in Series C funding. Participants in the round included new investors VMS Investment Group, Tasly Pharmaceutical Group, and Maxim Integrated, as well as returning backers 3E Bioventures Capital and Atinum Investment.
The company will be using the new financing to bring its CE Marked sensor, the Profusa Lumee Oxygen Platform, toward commercialization and continue development of another continuous biosensor focused on glucose detection.

Source: mobihealthnews - August 14, 2018 Category: Information Technology Source Type: news